5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details


臨床試験数 : 95 薬物数 : 119 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000041207
2021-01-012020-12-22A registered cohort study on progressive supranuclear palsy (PSP)A registered cohort study on progressive supranuclear palsy (PSP) progressive supranuclear palsyGold Standard:Diagnostic criteria of MDS for progressive supra-nuclear palsy (2017) and the Chinese clinical diagnostic criteria for progressive supra-nuclear palsy (2016).;Index test:The progression of PSP rating scales. Tau protein-related pathological examination (for example, Tau protein content in blood, Tau protein-related detection in cerebrospinal fluid in patients with cognitive impairment, etc.), and brain Tau PET imaging.;Huashan Hospital, Fudan UniversityNULLRecruiting4085BothTarget condition:100;Difficult condition:0China
2ChiCTR2000030512
2019-05-132020-03-05Clinical study of [18F]-APN-1607([18F]-PM-PBB3) PET on tau tangles in the brain of progressive supranuclear palsyClinical study of [18F]-APN-1607([18F]-PM-PBB3) PET on tau tangles in the brain of progressive supranuclear palsy progressive supranuclear palsyGold Standard:clinical diagnosis of progressive supranuclear palsy the movement disorder society criteria in 2017.(Mov Disord. 2017 Jun;32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.).;Index test:Standard uptake value ratio of [18F]-APN-1607([18F]-PM-PBB3);Huashan Hospital, Fudan UniversityNULLRecruiting4580BothTarget condition:26;Difficult condition:0China